← Back to Patent Explorer
US4666919A Expired / Lapsed US ⏱️ 0.0 years remaining

Stabilized pharmaceutical composition containing an isocarbostyril derivative

Assignee: Nisshin Seifun Group Inc
•
Filing: 1985-07-25
•
Granted: 1987-05-19
•
Expires: 2005-07-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A stabilized pharmaceutical composition containing 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril or an acid addition salt thereof as the active ingredient is now provided, in which the active ingredient compound is stabilized by addition of at least one of stabilizing agents selected from magnesium silicate, magnesium oxide, hydrotalcite and sodium hydrogen carbonate.

Inventors

  • 👤 Masao Ueno
  • 👤 Hironori Kubota

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 09:24
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K47/00; A61K47/02; A61P; A61P9/00

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 63 words
A stabilized pharmaceutical composition in the form of a solid preparation which comprises 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril or a pharmaceutical acceptable acid addition salt thereof as the active ingredient, and 0.5 to 20 parts by weight of one or more stabilizing agents selected from the group consisting of magnesium silicate, magnesium oxide, hydrotalcite and sodium hydrogen carbonate per one part by weight of the isocarbostyril compound.
Claim 2
Dependent Claim 63 words
A stabilized pharmaceutical composition in the form of a solid preparation which comprises 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril or a pharmaceutical acceptable acid addition salt thereof as the active ingredient, and 0.5 to 20 parts by weight of one or more stabilizing agents selected from the group consisting of magnesium silicate, magnesium oxide, hydrotalcite and sodium hydrogen carbonate per one part by weight of the isocarbostyril compound.
Claim 3
Dependent Claim 75 words
A stabilized pharmaceutical composition in the form of a solid preparation which comprises 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril or a pharmaceutically acceptable acid addition salt thereof as the active ingredient, and 0.5 to 20 parts by weight of one or more stabilizing agents selected from the group consisting of magnesium silicate, magnesium oxide, hydrotalcite and sodium hydrogen carbonate per one part by weight of the isocarbostyril compound, in association with a pharmaceutically acceptable solid carrier for the active ingredient.
Claim 4
Dependent Claim 75 words
A stabilized pharmaceutical composition in the form of a solid preparation which comprises 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril or a pharmaceutically acceptable acid addition salt thereof as the active ingredient, and 0.5 to 20 parts by weight of one or more stabilizing agents selected from the group consisting of magnesium silicate, magnesium oxide, hydrotalcite and sodium hydrogen carbonate per one part by weight of the isocarbostyril compound, in association with a pharmaceutically acceptable solid carrier for the active ingredient.
Claim 5
Dependent Claim 23 words
The composition as claimed in claim 1 or claim 2 in which the pharmaceutically acceptable acid addition salt of 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril is the hydrochloride.
Claim 6
Independent Claim 62 words
A method of stabilizing 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril or a pharmaceutically acceptable acid addition salt thereof, which comprises adding to and mixing with the isocarbostyril compound one or more stabilizing agents selected from the group consisting of magnesium silicate, magnesium oxide, hydrotalcite and sodium hydrogen carbonate in an amount of 0.5 to 20 parts by weight per one part by weight of the isocarbostyril compound.
Claim 7
Independent Claim 62 words
A method of stabilizing 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril or a pharmaceutically acceptable acid addition salt thereof, which comprises adding to and mixing with the isocarbostyril compound one or more stabilizing agents selected from the group consisting of magnesium silicate, magnesium oxide, hydrotalcite and sodium hydrogen carbonate in an amount of 0.5 to 20 parts by weight per one part by weight of the isocarbostyril compound.
Claim 8
Dependent Claim 49 words
The composition as claimed in claim 1 or claim 2 which is in the form of a solid preparation and which comprises a pharmaceutically acceptable acid addition salt of 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril and 1 to 3 parts by weight of magnesium silicate per one part by weight of the isocarbostyril compound.
Claim 9
Dependent Claim 47 words
The composition as claimed in claim 1 or claim 2 which is in the form of a solid preparation and which comprises a pharmaceutically acceptable acid addition salt of 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril and 1-3 parts by weight of magnesium oxide per one part by weight of the isocarbostyril compound.
Claim 10
Dependent Claim 46 words
The composition as claimed in claim 1 or claim 2 which is in the form of a solid preparation and which comprises a pharmaceutically acceptable acid addition salt of 4-(3-tert.-bytylamino-2-hydroxy)propoxy-2-methylisocarbostyril and 1-3 parts by weight of hydrotalcite per one part by weight of the isocarbostyril compound.
Claim 11
Dependent Claim 48 words
The composition as claimed in claim 1 or claim 2 which is in the form of a solid preparation and which comprises a pharmaceutically acceptable acid addition salt of 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril and 1-3 parts by weight of sodium hydrogen carbonate per one part by weight of the isocarbostyril compound.

References Cited (Backward Citations)

US4129565A Cited
GB2101990A Cited
US4526893A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-05-18 1990-11-17 1991-05-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-05-18 1994-11-17 1995-05-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-05-18 1998-11-17 1999-05-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag